Brand Name
Panretin
Generic Name
Alitretinoin
View Brand Information FDA approval date: September 10, 2019
Classification: Retinoid
Form: Gel
What is Panretin (Alitretinoin)?
Panretin ® gel is indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. Panretin ® gel is not indicated when systemic anti-KS therapy is required . There is no experience to date using Panretin ® gel with systemic anti-KS treatment.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment